The U.S. Court of Appeals for the Federal Circuit (CAFC) on Friday, July 25, transferred an appeal over an award issued in an ...

The appeal of a drug-patent dispute that allowed patent owner Alkermes PLC to keep $65.6 million in allegedly improper ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alkermes ( (ALKS) ) has shared an update.

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the ...

Stifel Nicolaus analyst Paul Matteis reiterated a Buy rating on Alkermes today and set a price target of $42.00. The company’s shares opened today at $28.98. Take advantage of TipRanks Premium at 50% ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Alkermes plc stands fourth on our list among the most ...

Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability ...